The estimated Net Worth of Terrance J Coughlin is at least $4.11 Million dollars as of 21 February 2020. Mr. Coughlin owns over 108,968 units of Endo International plc stock worth over $90,289 and over the last 8 years he sold ENDP stock worth over $0. In addition, he makes $4,018,300 as Chief Operating Officer and Executive Vice President at Endo International plc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Coughlin ENDP stock SEC Form 4 insiders trading
Terrance has made over 2 trades of the Endo International plc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 108,968 units of ENDP stock worth $31,884 on 21 February 2020.
The largest trade he's ever made was exercising 108,968 units of Endo International plc stock on 21 February 2020 worth over $31,884. On average, Terrance trades about 6,788 units every 49 days since 2017. As of 21 February 2020 he still owns at least 308,574 units of Endo International plc stock.
You can see the complete history of Mr. Coughlin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Terrance Coughlin biography
Terrance John Coughlin is Chief Operating Officer, Executive Vice President of the Company. In this role, Mr. Coughlin has responsibility for Manufacturing and Technical Operations and R&D across the enterprise. Most recently, Mr. Coughlin served as Vice President, Operations of Par Pharmaceutical Companies, Inc., a subsidiary of Endo. Prior to Endo’s acquisition of Par in September 2015, Mr. Coughlin was the Chief Operating Officer of Par Pharmaceutical Companies, Inc. Prior to joining Par, Mr. Coughlin held numerous leadership roles with Glenmark Generics, Inc. USA/Glenmark Generics Limited, most recently having served as the President and Chief Executive Officer of Glenmark Generics, Inc. USA/Glenmark Generics Limited. Prior to this, Mr. Coughlin had the overall responsibility for Glenmark’s North American, Western European and Eastern European generics businesses, as well as its global active pharmaceutical ingredient business and generics operations in India. Prior to joining Glenmark, Mr. Coughlin served as Senior Vice President at Dr. Reddy’s Laboratories, Inc. Mr. Coughlin began his career in 1988 with Wyckoff Chemical Company, Inc. Mr. Coughlin earned a B.S. in chemistry from Central Michigan University.
What is the salary of Terrance Coughlin?
As the Chief Operating Officer and Executive Vice President of Endo International plc, the total compensation of Terrance Coughlin at Endo International plc is $4,018,300. There are 1 executives at Endo International plc getting paid more, with Paul Campanelli having the highest compensation of $13,118,300.
How old is Terrance Coughlin?
Terrance Coughlin is 55, he's been the Chief Operating Officer and Executive Vice President of Endo International plc since 2016. There are 7 older and 9 younger executives at Endo International plc. The oldest executive at Endo International plc is Michael Hyatt, 74, who is the Independent Director.
What's Terrance Coughlin's mailing address?
Terrance's mailing address filed with the SEC is C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN, L2, .
Insiders trading at Endo International plc
Over the last 11 years, insiders at Endo International plc have traded over $3,455,441 worth of Endo International plc stock and bought 152,347 units worth $3,901,804 . The most active insiders traders include Silva Rajiv De, Paul Campanelli, and Shane Cooke. On average, Endo International plc executives and independent directors trade stock every 36 days with the average trade being worth of $12,163. The most recent stock trade was executed by Patrick A Barry on 29 March 2022, trading 59,298 units of ENDP stock currently worth $17,351.
What does Endo International plc do?
Endo is a specialty pharmaceutical company committed to helping everyone it serves live their best life through the delivery of quality, life-enhancing therapies. Its decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Together, it boldly transforms insights into treatments benefiting those who need them, when they need them.
What does Endo International plc's logo look like?
Complete history of Mr. Coughlin stock trades at Endo International plc
Endo International plc executives and stock owners
Endo International plc executives and other stock owners filed with the SEC include:
-
Paul Campanelli,
Chairman of the Board -
Terrance Coughlin,
Chief Operating Officer, Executive Vice President -
Blaise Coleman,
Pres, CEO & Director -
Blaise Coleman,
President, Chief Executive Officer, Director -
Matthew Maletta,
Executive Vice President, Chief Legal Officer -
Patrick Barry,
Executive Vice President and Chief Commercial Officer, U.S. Branded Business -
Patrick A. Barry,
Exec. VP & Pres of Global Commercial Operations -
Mark T. Bradley,
Exec. VP & CFO -
Roger Kimmel,
Senior Independent Director -
Shane Cooke,
Independent Director -
William Montague,
Independent Director -
Nancy Hutson,
Independent Director -
Michael Hyatt,
Independent Director -
M. Christine Smith,
Independent Director -
Mark Barberio,
Independent Director -
Jack Boyle,
Senior Vice President - Financial Planning & Analysis, Chief Accounting Officer, Controller -
Rahul Garella,
Executive Vice President, International Pharmaceuticals -
Domenico Ciarico,
Executive Vice President and Chief Commercial Officer, Sterile and Generics -
Joseph A. Barbarite,
Exec. VP of Global Quality and Compliance -
Tracy Basso,
Chief HR Officer -
Susan Williamson,
Sr. VP & Chief Compliance Officer -
Laure E. Park,
Sr. VP of Investor Relations & Corp. Affairs -
Ruth Thorpe,
Sr. VP of Information Technology & Chief Information Officer -
Robert Polke,
Exec. VP & Global Head of Operations -
Arthur J Higgins,
Director -
Douglas S Ingram,
Director -
Hemanth Jacob Varghese,
Pres. International Pharma -
Suketu Upadhyay,
EVP, Chief Financial Officer -
Antonio R Pera,
President, Par Pharmaceutical -
Joseph Ciaffoni,
President, U.S. Branded Pharma -
Carrie Ann Nichol,
SVP, Controller & CAO -
Mark T. Bradley,
EVP, Chief Financial Officer -
Frank B. Raciti,
VP, Controller and CAO -
Daniel Rudio,
Vice President, Controller -
Sharad Mansukani,
Director -
William Spengler,
Director -
Silva Rajiv De,
President & CEO -
John Delucca,
Director -
Brian Lortie,
President Branded Pharma -
Susan Hall,
EVP, CSO, Global Head of R&D -
Caroline B Manogue,
Exec. V.P., CLO & Secy -
Camille Farhat,
President, AMS, Inc. -
Ivan P. Gergel,
EVP, R&D and CSO -
Donald W De Golyer,
Chief Operating Officer,Pharma -
Mary Christine Smith,
Director -
George Apostol,
EVP, Global R&D -
Jennifer M Chao,
Director -
James Patrick Tursi,
Executive VP, Global R&D